RT Journal Article
SR Electronic
T1 Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187252
DO 10.1101/2020.09.03.20187252
A1 Agarwal, Anup
A1 Mukherjee, Aparna
A1 Kumar, Gunjan
A1 Chatterjee, Pranab
A1 Bhatnagar, Tarun
A1 Malhotra, Pankaj
A1 Latha, B
A1 Bundas, Sunita
A1 Kumar, Vivek
A1 Dosi, Ravi
A1 Khambholja, Janak Kumar
A1 de Souza, Rosemarie
A1 Mesipogu, Raja Rao
A1 Srivastava, Saurabh
A1 Dube, Simmi
A1 Chaudhary, Kiran
A1 S, Subash
A1 Mattuvar K, S. Anbuselvi
A1 Rajendran, V
A1 Sundararajaperumal, A
A1 Balamanikandan, P
A1 Maheswari, R S Uma
A1 Jayanthi, R
A1 Ragunanthanan, S
A1 Bhandari, Sudhir
A1 Singh, Ajeet
A1 Pal, Ashok
A1 Handa, Anjali
A1 Rankawat, Govind
A1 Kargirwar, Ketan
A1 Regi, Joyce
A1 Rathod, Darshana
A1 Pathrose, Edwin
A1 Bhutaka, Nirankar
A1 Patel, Mayur H
A1 Verma, Rahul J
A1 Malukani, Kamal
A1 Patel, Shivani
A1 Thakur, Apurv
A1 Joshi, Satish
A1 Kulkarni, Rashmi
A1 Suthar, Nilay N
A1 Shah, Nehal M
A1 Purohit, Hemang M
A1 Shah, Cherry K
A1 Patel, Monila N
A1 Shah, Saket
A1 Shah, Smit H
A1 Memon, Tehsim
A1 Beriwala, Vishal R
A1 Jashnani, Kusum
A1 Ezzy, Fatema
A1 Agrawal, Simran
A1 Bhadade, Rakesh
A1 N, Atish M
A1 Madke, Tushar
A1 Kavishwar, Vikash
A1 Waghmare, Ramesh
A1 Valvi, Nitin
A1 Chander, B Thrilok
A1 Sekhar, A Vinaya
A1 Maurya, Akhilesh Kumar
A1 Hemanth, K
A1 Nagamani, K
A1 Sudha, K
A1 Chandra, T Ravi
A1 Rao, K Tushara
A1 Vyshnavi, J
A1 Upadhyay, Rashmi
A1 Bahadur, Shalini
A1 Pathak, Rambha
A1 Seth, Shikha
A1 Gupta, Rakesh
A1 Saxena, Rita
A1 Dwivedi, Preksha
A1 Malik, Reeni
A1 Chourasia, Deepti
A1 Lalwani, Jaya
A1 Sharma, UM
A1 Marko, JL
A1 Suri, Amit
A1 Kumar, Vijay
A1 Kaushik, Rajnish
A1 Kodan, Parul
A1 Acharya, Bhabani Prasad
A1 Gaur, Kuldeep Kumar
A1 Gupta, Anubhav
A1 Sachdeva, Prerna
A1 Dogra, Shruti
A1 Jindal, Aikaj
A1 John, M Joseph
A1 Dhanju, Avtar Singh
A1 Khetrepal, Ranjana
A1 Sharma, Neeraj
A1 Kukar, Neetu
A1 Kavita, Divya
A1 Kumar, Rajesh
A1 Mahajan, Rajesh
A1 Singh, Gurpreet
A1 Kaur, Jaspreet
A1 Singh, Raminder Pal
A1 Bassi, Rajni
A1 Parikh, Swapneil
A1 Shrivastav, Om
A1 Shastri, Jayanthi
A1 Desai, Maherra
A1 Udupa, Shreevatsa
A1 Bafna, Varun A
A1 Barge, Vijay
A1 Madane, Rajendra
A1 Yadav, Sheetal
A1 Mishra, Sanjeev
A1 Bajpayee, Archana
A1 Garg, M K
A1 Bohra, G K
A1 Nag, Vijaylakshmi
A1 Anne, Puneeth Babu
A1 Nadeem, Mohd
A1 Singh, Pallavi
A1 Niwas, Ram
A1 Khaire, Niranjan Shiwaji
A1 Sharma, Rattiram
A1 Singh, Mini p
A1 Sachdeva, Naresh
A1 Sachdev, Suchet
A1 Hans, Rekha
A1 Suri, Vikas
A1 Yaddanapudi, L N
A1 Lakshmi, PVM
A1 Singh, Neha
A1 Bhushan, Divendu
A1 Kumar, Neeraj
A1 Tambe, Muralidhar
A1 Salvi, Sonali
A1 Kadgi, Nalini
A1 Sangle, Shashikala
A1 Nakate, Leena
A1 Joshi, Samir
A1 Karyakarte, Rajesh
A1 Goyanka, Suraj
A1 Sharma, Nimisha
A1 Verma, Nikhil
A1 Das, Asim
A1 Bahl, Monika
A1 Wadhwa, Nitya
A1 Bhat, Shreepad
A1 Deshmukh, Shweta
A1 Wagh, Vrushali
A1 Kulkarni, Atul
A1 Yardi, Tanvi
A1 Kalgud, Ram S
A1 Reddy, Purushottam
A1 Yevoor, Kavitha
A1 Gajula, Prashanth
A1 Maleyur, Vivek
A1 S, Medini
A1 HN, Mohith
A1 Gurtoo, Anil
A1 Sud, Ritika
A1 Pahuja, Sangeeta
A1 Prakash, Anupam
A1 Gogoi, Parijat
A1 Shukla, Shailja
A1 Reddy, D Himanshu
A1 Chandra, Tulika
A1 Pandey, Saurabh
A1 Maurya, Pradeep
A1 Wahid, Ali
A1 Kumar, Vivek
A1 Upadhyay, Kamlesh
A1 Bhatnagar, Nidhi
A1 Shah, Nilima
A1 Shah, Mamta
A1 Patel, Tarak
A1 Jaiswal, Ram Mohan
A1 Jain, Ashish
A1 Sharma, Shweta
A1 Rijhwani, Puneet
A1 Gupta, Naveen
A1 Patel, Tinkal C
A1 Solu, Mahesh G
A1 Patel, Jitendra
A1 Shah, Yash R
A1 Jarag, Mayur
A1 Godbole, Varsha
A1 Shah, Meenakshi
A1 Raj, Rikin
A1 Nagori, Irfan
A1 Jha, Pramod R
A1 Shah, Arti D
A1 Yeeli, Gowtham
A1 Jain, Archit
A1 Gill, Rooppreet Kaur
A1 Babu, KV Sreedhar
A1 Babu, B Suresh
A1 Mohan, Alladi
A1 Vengamma, B
A1 Sekhar, K Chandra
A1 Damam, Srinivasulu
A1 Narsimhulu, K
A1 Aparna, C
A1 Baleswari, G
A1 K, Ravindranath Reddy
A1 Chandrasekhar, P
A1 Panjwani, Sunil Jodharam
A1 Akholkar, Pankaj J
A1 Joshi, Kairavi Parthesh
A1 Shah, Pragnesh H
A1 Barvaliya, Manish
A1 Baldi, Milind
A1 Yadav, Ashok
A1 Gupta, Manoj
A1 Rawat, Nitin
A1 Chawda, Dilip
A1 Natarajan, M
A1 Sintha, M
A1 Kumar, David Pradeep
A1 Rabbani, Fathhur
A1 Khadke, Vrushali Khirid
A1 Patki, Dattatray
A1 Marathe, Sonali
A1 D Souza, Clyde
A1 Tadha, Vipul
A1 Arora, Satyam
A1 Gupta, Devendra Kumar
A1 Dua, Seema
A1 Chauhan, Nitu
A1 Chahar, Ajeet Singh
A1 Mammen, Joy John
A1 Kumar, Snehil
A1 Daniel, Dolly
A1 Singh, Ravindraa
A1 Dhat, Venkatesh
A1 Agarwal, Yogesh
A1 Arora, Sohini
A1 Pathak, Ashish
A1 Purohit, Manju
A1 Sharma, Ashish
A1 Sharma, Jayashree
A1 Madkaikar, Manisha
A1 Joshi, Kavita
A1 Yadav, Reetika Malik
A1 Bhagwat, Swarupa
A1 Karnik, Niteen D
A1 Gokhale, Yojana A
A1 Naik, Leena
A1 Margam, Sangita
A1 Das, Santasabuj
A1 Turuk, Alka
A1 Kumar, V Saravana
A1 Kanagasabai, K
A1 Sabarinathan, R
A1 Deshpande, Gururaj
A1 Sharma, Sharda
A1 Gunjikar, Rashmi
A1 Shete, Anita
A1 Phagiwala, Darpan
A1 Patil, Chetan
A1 Shingade, Snehal
A1 Jarande, Kajal
A1 Kaushal, Himanshu
A1 Yadav, Pragya
A1 Sapkal, Gajanan
A1 Abraham, Priya
YR 2020
UL http://medrxiv.org/content/early/2020/09/10/2020.09.03.20187252.abstract
AB Objectives: Convalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19. Design: Open-label, parallel-arm, phase II, multicentre, randomized controlled trial. Setting: Thirty-nine public and private hospitals across India. Participants: Hospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate > 24/min and SpO2 ≤ 93% on room air). Intervention: Participants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm. Main Outcome Measure: Composite of progression to severe disease (PaO2/FiO2<100) or all-cause mortality at 28 days post-enrolment. Results: Between 22 nd April to 14 th July 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7%) participants in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67, 1.77]. Mortality was documented in 34 (14.5%) and 31 (13.5%) participants in intervention and control arm, respectively [aOR) 1.06 95% CI: 0.61 to 1.83]. Interpretation: CP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that TB is a member of the National Task Force for COVID-19 which approved the protocol. AM, AA, GK, AT, TB, VS, KK, RS, SD, GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA, MM, RMY are employed with ICMR, the funding source for the trial. PC was an employee of ICMR during the trial. The funding source (ICMR) has no financial interest in the investigational product. No other author has any competing financial or non-financial interest.Clinical TrialCTRI/2020/04/024775Funding StatementThis multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved this study. The Central Implementation Team at ICMR was responsible for study design, study coordination, data analysis, data interpretation and writing of the report. Patient enrolment, data collection and actual conduct of the study was done at public and private hospitals independently and the investigators in ICMR had no role in it. The funding source has no financial interest in the investigational product. The corresponding author at ICMR had access to all the data, is the guarantor for the current work and holds final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics comittee at the Indian council Medical Research, India and Intitutional review boards of all participating institutes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual patient level data, collected in connection with the PLACID Trial, along with a data dictionary defining the variable fields has been developed and is available with the corresponding author. De-identified participant level data with data dictionary, or a sub-set thereof, may be made available upon written request to the corresponding author. Additional documents, including the study protocol, statistical analysis plan have been made available as supplementary files within the original submission. Results of secondary or sub-group analyses will be provided on request. Data will be made available, upon request once the trial is published. Data requests should be accompanied by a brief proposal outlining the analysis plan, which may be carried out with investigator support. A signed data access agreement may be needed to ensure data safety and compliance with national rules regarding data sharing.